Winston Kung's most recent trade in Janux Therapeutics Inc was a trade of 11,667 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics Inc | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,667 | 11,667 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 3,750 | 6,250 | - | 0 | Common Stock | |
| Corbus Pharmaceuticals Hol... | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 16,000 | 16,000 | - | - | Stock options (right to buy) | |
| Corbus Pharmaceuticals Hol... | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 4,800 | 10,366 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| ArriVent BioPharma Inc. | Winston Kung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Corbus Pharmaceuticals Hol... | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 5,566 | 5,566 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | |
| Corbus Pharmaceuticals Hol... | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2024 | 5,566 | 5,566 | - | - | Stock options (right to buy) | |
| Janux Therapeutics Inc | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 8,350 | 8,350 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 2,500 | 2,500 | - | 0 | Common Stock | |
| Janux Therapeutics Inc | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Nov 2022 | 2,560 | 10,600 | - | 0 | Common Stock | |
| Janux Therapeutics Inc | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Winston Kung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2022 | 9,375 | 9,375 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2022 | 4,000 | 210,034 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 20 Apr 2022 | 4,000 | 10,600 | - | 3.2 | 12,880 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 104,400 | 104,400 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 19 Aug 2021 | 5,000 | 6,600 | - | 3.2 | 16,100 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 5,000 | 214,034 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 03 Aug 2021 | 4,500 | 6,100 | - | 3.2 | 14,490 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 4,500 | 219,034 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Sale of securities on an exchange or to another person at price $ 33.82 per share. | 03 Aug 2021 | 4,500 | 1,600 | - | 33.8 | 152,178 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 4,500 | 223,534 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 08 Jul 2021 | 4,500 | 6,100 | - | 3.2 | 14,490 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Sale of securities on an exchange or to another person at price $ 33.75 per share. | 08 Jul 2021 | 4,500 | 1,600 | - | 33.8 | 151,875 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 04 Jun 2021 | 4,500 | 6,100 | - | 3.2 | 14,490 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2021 | 4,500 | 228,034 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Sale of securities on an exchange or to another person at price $ 33.75 per share. | 04 Jun 2021 | 4,500 | 1,600 | - | 33.8 | 151,875 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 50,337 | 50,337 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 03 May 2021 | 4,500 | 6,100 | - | 3.2 | 14,490 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2021 | 4,500 | 232,534 | - | - | Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Sale of securities on an exchange or to another person at price $ 33.75 per share. | 03 May 2021 | 4,500 | 1,600 | - | 33.8 | 151,875 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 08 Dec 2020 | 1,600 | 1,600 | - | 3.2 | 5,152 | Common Stock |
| PMV Pharmaceuticals Inc | Winston Kung | COO, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2020 | 1,600 | 237,034 | - | - | Stock Option (right to buy) |